Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SCN4A | P35499 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728559 | 0.88 | PTPN1 (0.49) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL29728542 | 0.86 | MEN1 (0.43) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL27641372 | 0.85 | TSHR (0.49) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL28709713 | 0.82 | KDM4E (0.54) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL8764787 | 0.81 | L3MBTL1 (0.55) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL28611098 | 0.80 | TDP1 (0.53) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL982574 | 0.79 | L3MBTL1 (0.58) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL2059537 | 0.79 | KDM4E (0.71) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL1951034 | 0.77 | KDM4E (0.41) | KMT2AMEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL10959076 | 0.77 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| CN-112020493-B | Method for producing urethane and method for producing isocyanate | 旭化成株式会社 | 2023-04-21 | — | — | CN | disclosed |
| US-11603355-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3938345-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113950471-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185830-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-2755949-B1 | FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-9090600-B2 | Fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadizol-5(4H)-one derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| EP-0325620-A1 | METHOD FOR THE PREPARATION OF AMIDINO-UREA DERIVATIVES | REANAL FINOMVEGYSZERGYAR (HU) | 1989-08-02 | — | — | EP | disclosed |
| WO-1988007990-A1 | METHOD FOR THE PREPARATION OF AMIDINO-UREA DERIVATIVES | REANAL FINOMVEGYSZERGYÁR (HU) | 1988-10-20 | — | — | WO | disclosed |
| US-4226883-A | Carbamate derivatives and method for manufacture thereof | YAMAMOTO IZURU | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | L3MBTL1 4844/4885SMN1; SMN2 2763/4885KMT2A 2429/4885 |
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | CYP4X1, CYP4B1, CYP4Z1 | L3MBTL1 499/4885SMN1; SMN2 1570/4885KMT2A 2404/4885 |
| US-11603355-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | L3MBTL1 4844/4885SMN1; SMN2 2763/4885KMT2A 2429/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | L3MBTL1 4844/4885SMN1; SMN2 2763/4885KMT2A 2429/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | L3MBTL1 4844/4885SMN1; SMN2 2763/4885KMT2A 2429/4885 |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | L3MBTL1 4844/4885SMN1; SMN2 2763/4885KMT2A 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.